Oncogenic viruses in the thrombocytopenic stage of experimental HIPA — plasmacytoma

Pedio, G; Rüttner, J. R.; Odermatt, Bernhard; Gut, D.

doi:10.1007/bf01934833

Cited by 4 publications

(4 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With advanced age comes immune system dampening and modulation that could potentially predispose to both malignancy and thrombocytopenia 3 . Other theories include an increase in antiplatelet antibody with carcinoma, as well as the presence of immune-modulating oncogenic viruses 6,7 .…”

Section: Figurementioning

confidence: 99%

A Case of Metastatic Prostate Cancer and Immune Thrombocytopenia

2017

View full text Add to dashboard Cite

Prostate cancer frequently metastasizes to bone, but bone marrow involvement is relatively less common. In advanced prostate cancer, significant bone marrow infiltration can result in hematologic abnormalities such as anemia and thrombocytopenia. We report the case of a patient who presented with a new diagnosis of thrombocytopenia at the same time that he presented with prostate cancer metastatic to bone. He was found to have immune thrombocytopenia (itp) which responded to treatment with steroids. We discuss this case and review the literature on itp in the setting of advanced malignancy.

show abstract

Section: Figurementioning

confidence: 99%

A Case of Metastatic Prostate Cancer and Immune Thrombocytopenia

2017

View full text Add to dashboard Cite

show abstract

“…Le bilan disponible était fait de PSA Total à 282.97 ng/ml, l'hémogramme montrait essentiellement une anémie sévère à 7.4 g/100 ml normochrome normocytaire, et thrombopénie sévère à 59 G/L ; Le myélogramme montrait un aspect cytologique faisant évoquer des métastases médullaires d'un cancer prostatique (Figure 1 (Pedio et al, 1974). Jalali et al (Jalali et al, 2004) rapportaient un cas présentant une asthénie profonde, douleur osseuse, et pollakiurie, chez un patient hospitalisé en hématologie pour bilan étiologique d'une thrombopénie comme le cas de cette étude.…”

Section: Observationunclassified

Cancer de la Prostate Révélé par un Myélogramme Pathologique: A Propos d’Un Cas

Mkoh Dikao,

Agounkpe,

Djiepti

et al. 2023

ESJ

View full text Add to dashboard Cite

La majorité des cancers de la prostate sont diagnostiqués à un stade tardif en Afrique subsaharienne. Les complications hématologiques du cancer de la prostate surviennent au cours d’une évolution péjorative. Nous rapportons un cas révélé par une complication hématologique. Un patient de 70 ans a présenté une bicytopénie. Il avait des antécédents de myocardiopathie et de polytransfusion. Il a été admis en hématologie pour recherche étiologique d’une bicytopénie sévère. La réalisation d’un myélogramme à visée de recherche étiologique a identifié des cellules métastatiques d’origine prostatique. L’examen anatomopathologie des carottes de biopsie prostatique a révélé un adénocarcinome prostatique infiltrant, score de Gleason 7 (4 + 3), ISUP (International Society of Urological Pathologie) 3. L’hormonothérapie et les transfusions sanguines associées aux bisphosphonates ont constitué l’essentiel du traitement. L’évolution sous ce traitement a été favorable sur le plan clinique avec une amélioration de l’état général et biologique avec une normalisation de la lignée rouge à 3mois de traitement et un PSA (Prostate Specific Antigen) au nadir après 6mois de traitement. Les complications hématologiques de la néoplasie prostatique notamment dues à l’envahissement médullaire sont source d’égarement diagnostique. Elles méritent d’être connues des cliniciens puisqu’elles peuvent être révélatrices de ce cancer au stade métastatique. The majority of prostate cancers are diagnosed at a late stage in sub-Saharan Africa. The haematological complications of prostate cancer occur during a pejorative course. We report a case revealed by a haematological complication. A 70-year-old patient presented with bicytopenia. He had a history of cardiomyopathy and polytransfusion. He was admitted to hematology for a etiological investigation of severe bicytopenia. Performing a myelogram for etiological research identified metastatic cells of prostate origin. The pathology examination of the prostate biopsy cores revealed an infiltrating prostatic adenocarcinoma, Gleason score 7 (4 + 3), ISUP (International Society of Urological Pathology) 3. Hormontherapy and blood transfusions associated with bisphosphonates were the factor essential of treatment. The outcome under this treatment was clinically favorable with an improvement in the general and biological condition with normalization of the red line at 3 months of treatment and a PSA (Prostate Specific Antigen) at nadir after 6 months of treatment. The haematological complications of prostatic neoplasia, in particular due to spinal cord invasion, are a source of diagnostic error. They deserve to be known to clinicians since they can be indicative of this cancer in the metastatic stage.

show abstract

“…A study reported thrombocytosis in pre-treatment subjects while thrombocytopenia was reported by other studies. 16,17,24,28 So many theories postulated the causes of this thrombocytopenia in these patients, as an increase in anti-platelet antibody induced by the cancer as well as the presence of immunemodulating oncogenic viruses; however the mechanism of this cancer ITP has not yet been elucidated. 18,28 In this work, the pretreatment PLT was within normal range, no thrombocytosis or thrombocytopenia was observed when compared with the treatment results.…”

Section: Prostate Cancer Pre-treatment and Treatmentmentioning

confidence: 99%

“…15 A number of studies indicated that an increased erythrocytic sedimentation rate (ESR) level is associated with worse survival; patients with higher ESR values in various malignancies, especially in solid cancers, had a shorter survival compared with those with normal ESR levels. [16][17][18][19][20] The risk of developing prostate cancer begins to increase at age 50 years in white men with none familial history and at age 40 years in black men with first-degree relative. 21 Risk increases with age, but unlike other cancers, prostate cancer has no peak age or modal distribution.…”

Section: Introductionmentioning

confidence: 99%

The use of peripheral blood cells as an assessment of inflammation in prostate cancer in patients attending in surgery department at ESUT teaching hospital, Parklane, Enugu, Nigeria

Soronnadi

Ibeh²,

Ugwene

et al. 2020

Int J Res Med Sci

View full text Add to dashboard Cite

Background: Full blood count (FBC) is a prerequisite investigation requested from all prostate cancer (PCa) patients pre and post treatment, poor parameter influences the outcome of cancers.Methods: Total subjects consisted of 84 male subjects between the ages 41 to >80 years. Longitudinal study was conducted. Controls and test samples were collected at diagnosis and at different stages of the treatment. Demographic information was obtained using a questionnaire. The data was analyzed using IBM statistical package for social sciences (SPSS) PC, version 20.0; SPSS Inc., Chicago, III., USA; the receiver operating characteristic curve (ROC) curve was obtained via neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR) and platelet-to-lymphocyte ratio (PLR) ratios cut-off determinations. Cox proportional-hazards regression analyses the prognostic factors (duration, ratios) and overall survival (diagnosis to death or last follow-up). A paired sample t-test compared test of significance in pre/post treatment results. The analysis of variance (ANOVA) and Tukey HSD post-hoc, test susceptibility within age groups was done.Results: Increased NLR and LMR were significantly associated with increased hazard ratio (HR) and OS at p<0.05 while PLR, no significant difference at P>0.05 in PCa. In complete blood count (CBC) and erythrocytic sedimentation rate (ESR), control and treatment period, all red blood cell (RBC) parameters showed a significant decrease at p<0.05 in treatment results compared to the pre-treatment results while total platelet (TPLT), total white blood cells (TWBC), NC, LC, ESR showed significant increase at p<0.05 in treatment results compared to pre-treatment results. Age group 41-50 years showed more susceptibility than other age groups with significant decrease at p<0.05 in NC, LC and increased MC.Conclusions: This study supports CBC and ESR biomarkers as a prognostic tool in early detection, treatment and monitoring of disease progression in these subjects.

show abstract

Oncogenic viruses in the thrombocytopenic stage of experimental HIPA — plasmacytoma

Cited by 4 publications

References 3 publications

A Case of Metastatic Prostate Cancer and Immune Thrombocytopenia

A Case of Metastatic Prostate Cancer and Immune Thrombocytopenia

Cancer de la Prostate Révélé par un Myélogramme Pathologique: A Propos d’Un Cas

The use of peripheral blood cells as an assessment of inflammation in prostate cancer in patients attending in surgery department at ESUT teaching hospital, Parklane, Enugu, Nigeria

Contact Info

Product

Resources

About